Modified FOLFOX-4 as first-line and salvage treatment in advanced gastric cancer.

Abstract

BACKGROUND/AIMS:

Oxaliplatin, leucovorin and fluorouracil combination therapy (FOLFOX) was effective and safe treatment in AGC. The aim of this study was to evaluate the efficacy and safety of the modified FOLFOX-4 using low dose leucovorin for patients with advanced gastric cancer and analyze the efficacy of this regimen as first-line and salvage treatment.

METHODOLOGY:

Forty-two patients with recurrent or metastatic gastric cancer received oxaliplatin 85 mg/m2 and leucovorin 20 mg/m2 followed by 5-FU bolus 400 mg/m2 and then 5-FU 600 mg/m2 every 2 weeks.

RESULTS:

1 (2.4%) complete response and 10 (23.8%) partial responses were observed. Stable disease and progressive disease were observed in 18 (42.9%) and 13 (30.9%). Median overall survival and progression free survival were 9.3 and 4.9 months. Among them, 26 (61.9%) and 16 (38.1%) of patients were treated as first-line and salvage treatment. Median overall survivals in the first-line and salvage treatment were 11.1 and 8.2 months respectively. And progression free survivals in first-line and salvage treatment were 6.0 and 4.7 month. Performance status was the only independent prognostic factor in overall survival in advanced gastric cancer.

CONCLUSIONS:

Our study showed modified FOLFOX-4 regimen had significant effects and favorable toxicities as first-line and salvage treatment for patients with advanced gastric cancer.

• Authors: Yang Hyun Baek, Seok Reyol Choi, Jin Seoh Jang, Myung Hwan Roh, Jong Hun Lee, Jong Jin Won, Chang Min Lee
• Journal: Hepato-gastroenterology (Hepatogastroenterology) 2011 Jan-Feb Vol. 58 Issue 105 Pg. 251-6 ISSN: 0172-6390 [Print] Greece
• PMID: 21510324 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Organoplatinum Compounds
• Leucovorin
• Fluorouracil

Topics

• Adult
• Aged
• Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
• Disease Progression
• Female
• Fluorouracil (adverse effects, therapeutic use)
• Humans
• Leucovorin (adverse effects, therapeutic use)
• Male
• Middle Aged
• Organoplatinum Compounds (adverse effects, therapeutic use)
• Prognosis
• Proportional Hazards Models
• Salvage Therapy
• Stomach Neoplasms (drug therapy, pathology)
• Survival Rate
• Treatment Outcome